Milestone Pharmaceuticals Q1 Revenue $238,000
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 14 hours ago
0mins
Should l Buy MIST?
Reports Q1 revenue $238,000, consensus $37.64M. "We're excited to report on our first quarter of sales for CARDAMYST for paroxysmal supraventricular tachycardia, or PSVT. Healthcare professionals' initial reaction to the product is positive and we are very encouraged by the early breadth of unique prescribers writing for their patients," said Joseph Oliveto, President and CEO of Milestone Pharmaceuticals. "Gaining Express Scripts' national formulary coverage in March reflects meaningful early payor adoption, highlighting the value CARDAMYST offers to insurers. We are also observing clinician enthusiasm for expanded development of etripamil in patients with AFib-RVR, as we have now kicked off our Phase 3 pivotal trial and are actively engaging potential clinical trial sites."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MIST?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MIST
Wall Street analysts forecast MIST stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.900
Low
8.00
Averages
8.00
High
8.00
Current: 1.900
Low
8.00
Averages
8.00
High
8.00
About MIST
Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, and other cardiovascular indications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Milestone Pharmaceuticals Shares Drop 9% Following Disappointing Earnings Report
- Disappointing Earnings Report: Milestone Pharmaceuticals' quarterly earnings report revealed that despite its new drug Cardamyst receiving FDA approval and generating $238,000 in sales during the first quarter, shares fell over 9%, reflecting investor disappointment with the results.
- Surging Commercial Expenses: The company's commercial spending to promote Cardamyst increased by 52% year-over-year, leading to a net loss that deepened to over $26 million ($0.20 per share), compared to a loss of under $20.8 million in the previous year, indicating significant financial pressure from high marketing costs.
- Missed Market Expectations: Analysts had expected Milestone to generate over $56 million in revenue and forecasted a profit of $0.23 per share, but the actual performance fell far short of these expectations, highlighting challenges in the new drug's market penetration.
- Optimistic Future Outlook: Despite the current disappointing performance, Milestone has nearly $184 million in cash and short-term investments, which is expected to sustain operations into the second half of 2027, providing the company ample time to boost Cardamyst's market acceptance and explore additional indications.
See More
Milestone Pharmaceuticals Reports Q1 2026 Earnings with Early Commercial Success
- First Earnings Report: Milestone Pharmaceuticals reported its first earnings for Q1 2026, with CARDAMYST generating $0.2 million in sales, marking the commercial launch for treating acute episodes of paroxysmal supraventricular tachycardia (PSVT), despite being a partial quarter.
- Coverage Improvement: By the end of April, the company captured approximately 600 prescriptions, estimating that 25% of commercially insured patients have quality coverage for CARDAMYST, significantly de-risking the launch and enhancing future sales potential.
- Strong Financial Position: As of March 31, 2026, the company reported approximately $184 million in cash and short-term investments, primarily due to a $75 million cash payment from a royalty purchase agreement with RTW and $19 million in net proceeds, ensuring funding for ongoing product development and market execution.
- Clinical Trial Initiation: The company has initiated the Phase III ReVeRa-301 trial, expecting to enroll its first patient in the second half of 2026, with the study projected to last around two years, targeting 150 to 200 total events, thereby advancing the development of atrial fibrillation treatments.
See More
Milestone Pharmaceuticals Reports Q1 Earnings Miss
- Earnings Miss: Milestone Pharmaceuticals reported a Q1 GAAP EPS of -$0.20, missing expectations by $0.39, indicating significant challenges in profitability that may affect investor confidence.
- Revenue Decline: The company generated only $0.24 million in revenue for the quarter, falling short by $37.4 million, reflecting severe deficiencies in product sales and market demand, which could lead to future cash flow constraints.
- Cash Reserves Increase: As of March 31, 2026, Milestone's cash and short-term investments totaled $184.2 million, a significant rise from $106.0 million on December 31, 2025, indicating improvements in financial management.
- Funding Outlook: The company expects its current cash reserves to cover operating expenses and capital expenditures into the second half of 2027, including costs associated with the upcoming Phase 3 trial in AFib-RVR, demonstrating a commitment to ongoing research and development.
See More
Milestone Pharmaceuticals to Announce Q1 Earnings on May 13
- Earnings Announcement: Milestone Pharmaceuticals is set to release its Q1 2023 earnings report on May 13 before market open, drawing significant investor attention that could impact stock performance.
- EPS Expectations: The consensus EPS estimate stands at $0.19, indicating a cautiously optimistic outlook on the company's profitability, although there has been one upward and one downward revision in EPS estimates over the last three months.
- Revenue Forecast: The consensus revenue estimate is $37.64 million, reflecting a degree of market confidence in Milestone's sales performance for the quarter, with one upward revision and no downward revisions in revenue estimates during the past three months.
- Market Reaction Anticipation: As the earnings announcement approaches, investor interest in Milestone Pharmaceuticals is increasing, particularly given the challenges faced by its CARDAMYST product, which may influence investor decision-making.
See More
Milestone Pharmaceuticals Launches CARDAMYST Registry Study
- Study Design Unveiled: Milestone Pharmaceuticals presented the RESET-PSVT study design at the 2026 Cardiovascular Nursing Symposium, aiming to generate real-world evidence on CARDAMYST (etripamil) in patients with paroxysmal supraventricular tachycardia (PSVT), with an estimated enrollment of 450 patients across approximately 20 electrophysiology and cardiology sites.
- Clinical Application Expansion: The RESET-PSVT study will evaluate usage patterns of CARDAMYST, including PSVT episode frequency and medication usage, aiming to deepen understanding of patient quality of life and healthcare utilization in routine care, thereby supporting future scientific dialogue with robust data.
- Patient Feedback Collection: The study will collect patient-reported outcomes through surveys from both patients and healthcare providers, helping researchers better understand the practical application of CARDAMYST in PSVT management, and is expected to provide critical clinical insights for healthcare providers.
- Future Results Sharing: Results from the study are anticipated to be shared at future scientific conferences and in peer-reviewed publications, further enhancing the recognition of CARDAMYST's value in acute PSVT management, marking the first registry of its kind in this field.
See More
Milestone Pharmaceuticals Reports Q4 and FY 2025 Results with CARDAMYST Updates
- Financial Performance: Milestone Pharmaceuticals reported a wider net loss of $17.4 million for Q4 2025, translating to $0.16 per share, compared to a loss of $12.4 million or $0.19 per share in the previous year, indicating financial pressures during the product launch phase.
- Revenue Source: The company recorded $1.54 million in revenue for Q4 2025 from a milestone payment under its licensing agreement with Corxel Pharmaceuticals, marking an initial success in the commercialization of CARDAMYST following its FDA approval in the U.S.
- Product Approval and Marketing: CARDAMYST received FDA approval in December 2025 as the first self-administered nasal spray, with a sales team of 60 representatives expected to enhance market penetration in the cardiology sector.
- Future Plans: Milestone plans to conduct a Phase 3 registrational program to evaluate Etripamil for acute atrial fibrillation control, intending to leverage the initial PSVT indication to facilitate subsequent regulatory approvals.
See More
Milestone Pharmaceuticals Shares Drop 9% Following Disappointing Earnings Report
- Disappointing Earnings Report: Milestone Pharmaceuticals' quarterly earnings report revealed that despite its new drug Cardamyst receiving FDA approval and generating $238,000 in sales during the first quarter, shares fell over 9%, reflecting investor disappointment with the results.
- Surging Commercial Expenses: The company's commercial spending to promote Cardamyst increased by 52% year-over-year, leading to a net loss that deepened to over $26 million ($0.20 per share), compared to a loss of under $20.8 million in the previous year, indicating significant financial pressure from high marketing costs.
- Missed Market Expectations: Analysts had expected Milestone to generate over $56 million in revenue and forecasted a profit of $0.23 per share, but the actual performance fell far short of these expectations, highlighting challenges in the new drug's market penetration.
- Optimistic Future Outlook: Despite the current disappointing performance, Milestone has nearly $184 million in cash and short-term investments, which is expected to sustain operations into the second half of 2027, providing the company ample time to boost Cardamyst's market acceptance and explore additional indications.
See More
Milestone Pharmaceuticals Reports Q1 2026 Earnings with Early Commercial Success
- First Earnings Report: Milestone Pharmaceuticals reported its first earnings for Q1 2026, with CARDAMYST generating $0.2 million in sales, marking the commercial launch for treating acute episodes of paroxysmal supraventricular tachycardia (PSVT), despite being a partial quarter.
- Coverage Improvement: By the end of April, the company captured approximately 600 prescriptions, estimating that 25% of commercially insured patients have quality coverage for CARDAMYST, significantly de-risking the launch and enhancing future sales potential.
- Strong Financial Position: As of March 31, 2026, the company reported approximately $184 million in cash and short-term investments, primarily due to a $75 million cash payment from a royalty purchase agreement with RTW and $19 million in net proceeds, ensuring funding for ongoing product development and market execution.
- Clinical Trial Initiation: The company has initiated the Phase III ReVeRa-301 trial, expecting to enroll its first patient in the second half of 2026, with the study projected to last around two years, targeting 150 to 200 total events, thereby advancing the development of atrial fibrillation treatments.
See More
Milestone Pharmaceuticals Reports Q1 Earnings Miss
- Earnings Miss: Milestone Pharmaceuticals reported a Q1 GAAP EPS of -$0.20, missing expectations by $0.39, indicating significant challenges in profitability that may affect investor confidence.
- Revenue Decline: The company generated only $0.24 million in revenue for the quarter, falling short by $37.4 million, reflecting severe deficiencies in product sales and market demand, which could lead to future cash flow constraints.
- Cash Reserves Increase: As of March 31, 2026, Milestone's cash and short-term investments totaled $184.2 million, a significant rise from $106.0 million on December 31, 2025, indicating improvements in financial management.
- Funding Outlook: The company expects its current cash reserves to cover operating expenses and capital expenditures into the second half of 2027, including costs associated with the upcoming Phase 3 trial in AFib-RVR, demonstrating a commitment to ongoing research and development.
See More
Milestone Pharmaceuticals to Announce Q1 Earnings on May 13
- Earnings Announcement: Milestone Pharmaceuticals is set to release its Q1 2023 earnings report on May 13 before market open, drawing significant investor attention that could impact stock performance.
- EPS Expectations: The consensus EPS estimate stands at $0.19, indicating a cautiously optimistic outlook on the company's profitability, although there has been one upward and one downward revision in EPS estimates over the last three months.
- Revenue Forecast: The consensus revenue estimate is $37.64 million, reflecting a degree of market confidence in Milestone's sales performance for the quarter, with one upward revision and no downward revisions in revenue estimates during the past three months.
- Market Reaction Anticipation: As the earnings announcement approaches, investor interest in Milestone Pharmaceuticals is increasing, particularly given the challenges faced by its CARDAMYST product, which may influence investor decision-making.
See More
Milestone Pharmaceuticals Launches CARDAMYST Registry Study
- Study Design Unveiled: Milestone Pharmaceuticals presented the RESET-PSVT study design at the 2026 Cardiovascular Nursing Symposium, aiming to generate real-world evidence on CARDAMYST (etripamil) in patients with paroxysmal supraventricular tachycardia (PSVT), with an estimated enrollment of 450 patients across approximately 20 electrophysiology and cardiology sites.
- Clinical Application Expansion: The RESET-PSVT study will evaluate usage patterns of CARDAMYST, including PSVT episode frequency and medication usage, aiming to deepen understanding of patient quality of life and healthcare utilization in routine care, thereby supporting future scientific dialogue with robust data.
- Patient Feedback Collection: The study will collect patient-reported outcomes through surveys from both patients and healthcare providers, helping researchers better understand the practical application of CARDAMYST in PSVT management, and is expected to provide critical clinical insights for healthcare providers.
- Future Results Sharing: Results from the study are anticipated to be shared at future scientific conferences and in peer-reviewed publications, further enhancing the recognition of CARDAMYST's value in acute PSVT management, marking the first registry of its kind in this field.
See More
Milestone Pharmaceuticals Reports Q4 and FY 2025 Results with CARDAMYST Updates
- Financial Performance: Milestone Pharmaceuticals reported a wider net loss of $17.4 million for Q4 2025, translating to $0.16 per share, compared to a loss of $12.4 million or $0.19 per share in the previous year, indicating financial pressures during the product launch phase.
- Revenue Source: The company recorded $1.54 million in revenue for Q4 2025 from a milestone payment under its licensing agreement with Corxel Pharmaceuticals, marking an initial success in the commercialization of CARDAMYST following its FDA approval in the U.S.
- Product Approval and Marketing: CARDAMYST received FDA approval in December 2025 as the first self-administered nasal spray, with a sales team of 60 representatives expected to enhance market penetration in the cardiology sector.
- Future Plans: Milestone plans to conduct a Phase 3 registrational program to evaluate Etripamil for acute atrial fibrillation control, intending to leverage the initial PSVT indication to facilitate subsequent regulatory approvals.
See More
